Keep your eye on GlaxoSmithKline. The UK-based multinational drug-maker represents the future, both as a mass-producer of the vaccines that we pray will finally defeat Covid-19 and as a beacon of the way shareholder capitalism will re-position itself in the post-pandemic era.
GSK last week announced a collaboration with its French rival Sanofi to create a Covid-19 vaccine that it aims to manufacture at the rate of ‘hundreds of millions of doses annually’ by the end of next year.
Already a subscriber? Log in
Get 10 issues
for $10
Subscribe to The Spectator Australia today for the next 10 magazine issues, plus full online access, for just $10.
- Delivery of the weekly magazine
- Unlimited access to spectator.com.au and app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Unlock this article
You might disagree with half of it, but you’ll enjoy reading all of it. Try your first month for free, then just $2 a week for the remainder of your first year.
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in